DOCSLIB.ORG

Structure/Function Studies of the High Affinity Na /Glucose Cotransporter

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Structure/Function Studies of the High Affinity Na +/Glucose Cotransporter (SGLT1) by Tiemin Liu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Institute of Medical Sciences University of Toronto Copyright 2009 by Tiemin Liu Abstract Structure/Function Studies of the High Affinity Na +/Glucose Cotransporter (SGLT1) Tiemin Liu Doctor of Philosophy Institute of Medical Sciences University of Toronto, 2009 The high affinity sodium/glucose cotransporter (SGLT1) couples transport of Na + and glucose. Investigation of the structure/function relationships of the sodium/glucose transporter (SGLT1) is crucial to understanding co-transporter mechanism. In the first project, we used cysteine-scanning mutagenesis and chemical modification by methanethiosulphonate (MTS) derivatives to test whether predicted TM IV participates in sugar binding. Charged and polar residues and glucose/galactose malabsorption (GGM) missense mutations in TM IV were replaced with cysteine. Mutants exhibited sufficient expression to be studied in detail using the two-electrode voltage-clamp method in Xenopus laevis oocytes and COS-7 cells. The results from mutants T156C and K157C suggest that TM IV participates in sugar interaction with SGLT1. This work has been published in Am J Physiol Cell Physiol 295 (1) , C64-72, 2008 . The crystal structure of Vibrio parahaemolyticus SGLT (vSGLT) was recently published (1) and showed discrepancy with the predicted topology of mammalian SGLT1 in the region surrounding transmembrane segments IV-V. Therefore, in the second project, we investigated the topology in this region, thirty-eight residues from I143 to A180 in the N-terminal half of rabbit SGLT1 were individually replaced with cysteine II and then expressed in COS-7 cells or Xenopus laevis oocytes. Based on the results from biotinylation of mutants in intact COS-7 cells, MTSES accessibility of cysteine mutants expressed in COS-7 cells, effect of substrate on the accessibility of mutant T156C in TM IV expressed in COS-7 cells, and characterization of cysteine mutants in TM V expressed in Xenopus laevis oocytes, we suggest that the region including residues 143-180 forms part of the Na +- and sugar substrate-binding cavity. Our results also suggest that TM IV of mammalian SGLT1 extends from residue 143-171 and support the crystal structure of vSGLT. This work has been published in Biochem Biophys Res Commun 378 (1) , 133- 138, 2009 Previous studies established that mutant Q457C human SGLT1 retains full activity, and sugar translocation is abolished in mutant Q457R or in mutant Q457C following reaction with methanethiosulfonate derivatives, but Na + and sugar binding remain intact. Therefore, in the third project, we explored the mechanism by which modulation of Q457 abolishes transport, Q457C and Q457R of rabbit SGLT1 expressed in Xenopus laevis oocytes were studied using chemical modification, the two-electrode voltage-clamp technique and computer model simulations. Our results suggest that glutamine 457, in addition to being involved in sugar binding, is a residue that is sensitive to conformational changes of the carrier. This work has been published in Biophysical Journal 96 (2) , 748-760, 2009. Taken together our study along with previous biochemical characterization of SGLT1 and crystal structure of vSGLT, we propose a limited structural model that attempts to bring together the functions of substrate binding (Na + and sugar), coupling, and translocation. We propose that both Na + and sugar enter a hydrophilic cavity formed III by multiple transmembrane helices from both N-terminal half of SGLT1 and C-terminal half of SGLT1, analogous to all of the known crystal structures of ion-coupled transporters (the Na +/leucine transporter, Na +/aspartate transporter and lactose permease). The functionally important residues in SGLT1 (T156 and K157 in TM 4, D454 and Q457 in TM 11) are close to sugar binding sites. IV Acknowledgements I would like to acknowledge the valuable insights of my committee members, Dr. Peter Backx and Dr. Robert Tsushima. I would also like to thank my lab mates: Steven Huntley and Daniel Krofchick for their help with the Xenopus laevis oocyte expression system, the two-electrode voltage- clamp technique, and computer model simulations; Pam Speight for her excellent technical assistance and mutant preparation; Neil Goldenberg for his help with the COS-7 cell expression system; and Sandy McGugan and Fong Tsang for keeping me organized. To the various members of the Membrane Biology Research Group, especially Dr. David Clarke, Dr. Tip Loo, Claire Bartlett, and Dr. Reinhart Reithmeier, I wish to express my deepest gratitude for their helpful discussions and for guiding me into the world of membrane proteins. Finally, with much gratitude, I would like to thank my supervisor, Mel Silverman for his continuous support and valuable guidance throughout my Ph.D. I only hope the work I will endeavour in the future will make him proud of his investment in me. V Dedication To my parents and family VI Contents Contents 1 Introduction……………………………………………………………………… 1 1.1 Membrane transport in life……………………………………………. 1 1.2 Glucose transporters in humans………………………………………. 3 1.3 Sodium/glucose cotransporters……………………………………….. 6 1.4 Experimental techniques for studies on sodium/glucose cotransporters. 14 1.4.1 Xenopus laevis oocyte expression system…………………… 14 1.4.2 Two-electrode voltage-clamp technique…………………….. 17 1.5 The high affinity sodium/glucose cotransporter 1 (SGLT1)………….. 18 1.5.1 Structure of SGLT1…………………………………………. 19 1.5.2 Function of SGLT1…………………………………………. 22 1.5.2.1 Steady state transport kinetics of SGLT1…………. 23 1.5.2.2 Pre-steady state transport kinetics of SGLT1……… 27 1.5.3 Functional disorders of the SGLT1 (Glucose-galactose malabsorption)……………………………………………………... 28 1.6 Experimental rationale………………………………………………… 32 2 Materials and methods…………………………………………………………... 35 2.1 Molecular biology……………………………………………………... 35 2.2 Oocyte preparation and injection……………………………………… 35 2.3 Electrophysiology using two-microelectrode voltage clamp…………. 38 VII 2.4 Transient current measurements………………………………………. 40 2.5 Phloridzin affinity measurements…………………………………….. 42 2.6 Protocols for chemical modification………………………………….. 43 2.7 State model simulations……………………………………………….. 43 2.8 Cell transfection and western blot detection………………………….. 44 2.9 αMG uptake experiment………………………………………………. 44 2.10 Endo H and PNGase F deglycosylation analysis……………………. 45 2.11 Labeling of surface expressed wild type or mutants in COS-7 cells with biotin-MTSEA……………………………………………………….. 45 2.12 Statistical comparisons of means……………………………………. 46 3 Transmembrane IV of the high affinity sodium/glucose cotransporter participates in sugar binding………………………………………………………. 47 3.1 Summary………………………………………………………………. 47 3.2 Introduction……………………………………………………………. 48 3.3 Results…………………………………………………………………. 50 3.3.1 Characterization of mutant K157C………………………….. 51 3.3.1.1 Pre-steady state behavior of mutant K157C 51 compared to WT…………………………………………… 3.3.1.2 Site-directed alkylation of cysteine 157 (K157C) 53 rescued activity of SGLT1………………………………… 3.3.1.3 Steady state αMG induced Na + currents of K157C and K157C-MTSEA………………………………………. 61 VIII 3.3.2 Characterization of mutant T156C………………………….. 63 3.3.2.1 Steady state transport kinetics of T156C………….. 63 3.3.2.2 Apparent affinity of T156C for phloridzin………… 64 3.3.2.3 Chemical modification of T156C by MTS reagents. 65 3.4 Discussion……………………………………………………………... 68 4. Reanalysis of structure/function correlations in the region of transmembrane segments 4 and 5 of the rabbit sodium/glucose cotransporter……..………………. 71 4.1 Summary………………………………………………………………. 71 4.2 Introduction……………………………………………………………. 72 4.3 Results…………………………………………………………………. 73 4.3.1 Expression and αMG transport activity of mutants in COS-7 cells………………………………………………………………… 73 4.3.2 Determination of topology for TMs IV-V…………………… 76 4.3.2.1 Biotinylation of mutants in intact COS-7 cells……. 76 4.3.2.2 MTSES accessibility of cysteine mutants expressed in COS-7 cells……………………………………………... 78 4.3.3 Determination of functions for TMs IV-V…………………... 81 4.3.3.1 Effect of substrate on the accessibility of mutant T156C in TM IV expressed in COS-7 cells………………... 81 4.3.3.2 Characterization of cysteine mutants I177C, Y178C and A180C in TM V expressed in Xenopus laevis oocytes.. 83 4.4 Discussion…………………………………………………………….. 85 IX 5. Effects on conformational states of the rabbit sodium/glucose cotransporter through modulation of polarity and charge at glutamine 457……………………... 88 5.1 Summary………………………………………………………………. 88 5.2 Introduction……………………………………………………………. 89 5.3 Results…………………………………………………………………. 90 5.3.1 Steady State Kinetics of Mutant Q457C of Rabbit SGLT1…. 90 5.3.2 Pre-Steady State Kinetics of Mutants Q457C and Q457R of Rabbit SGLT1……………………………………………………... 92 5.3.3 Chemical Modification of Mutant Q457C of Rabbit SGLT1 by MTS Reagents………………………………………………….. 96 5.3.3.1 Effect of MTSET on voltage sensitivity and charge transfer of mutant Q457C…………………………………. 96 5.3.3.2 Effects of MTSET on sugar transport and sugar binding of mutant Q457C…………………………………. 97 5.3.3.3 Effect of MTSES or MTSEA on mutant Q457C….. 98 5.3.4 Phloridzin Affinity…………………………………………... 99 5.3.5 Decay Constants of Q457C of Rabbit SGLT1………………. 100 5.3.6 Model Simulations…………………………………………... 107 5.4 Discussion……………………………………………………………... 111 6. Structural implications of structure-function studies in SGLT1..……………….
Recommended publications
  • Fructose Diet-Induced Hypertension

    Fructose Diet-Induced Hypertension

    Possible Involvement of Up-regulated Salt Dependent Glucose Transporter-5 (SGLT5) in High- fructose Diet-induced Hypertension Hiroaki Hara Saitama Medical Center, Saitama Medical University Kaori Takayanagi Saitama Medical Center, Saitama Medical University Taisuke Shimizu Saitama Medical Center, Saitama Medical University Takatsugu Iwashita Saitama Medical Center, Saitama Medical University Akira Ikari Gifu Pharmaceutical University Hajime Hasegawa ( [email protected] ) Dept. of Nephrology and Hypertension, Saitama Medical Center, Saitama Medical University, Kamoda 1981, Kawagoe, Saitama 350-8550, Japan. Research Article Keywords: salt sensitive hypertension, salt reabsorption, extracellular volume, glucose Posted Date: January 11th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-122315/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/21 Abstract Excessive fructose intake causes a variety of adverse conditions (e.g., obesity, hepatic steatosis, insulin resistance and uric acid overproduction). Particularly, high fructose-induced hypertension is the most common and signicant pathological setting, however, its underlying mechanisms are not established. We investigated these mechanisms in 7-week-old male SD rats fed a diet containing 60% glucose (GLU) or 60% fructose (FRU) for 3, 6, or 12 weeks. Daily food consumption was measured to avoid between- group discrepancies in caloric/salt intake, adjusting for feeding amounts. The FRU rats' mean blood pressure was signicantly higher and fractional sodium excretion (FENa) was signicantly lower, indicating that the high-fructose diet caused salt retention. The FRU rats' kidney weight and glomerular surface area were greater, suggesting that the high-fructose diet induced an increase in extracellular uid volume.
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics

    Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics

    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
  • Cystine–Glutamate Antiporter Xct Deficiency Suppresses Tumor Growth While Preserving Antitumor Immunity

    Cystine–Glutamate Antiporter Xct Deficiency Suppresses Tumor Growth While Preserving Antitumor Immunity

    Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity Michael D. Arensmana, Xiaoran S. Yanga, Danielle M. Leahya, Lourdes Toral-Barzaa, Mary Mileskia, Edward C. Rosfjorda, Fang Wanga, Shibing Dengb, Jeremy S. Myersa, Robert T. Abrahamb, and Christina H. Enga,1 aOncology Research & Development, Pfizer, Pearl River, NY 10965; and bOncology Research & Development, Pfizer, San Diego, CA 92121 Edited by William G. Kaelin Jr., Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, and approved April 2, 2019 (received for review September 1, 2018) T cell-invigorating cancer immunotherapies have near-curative Thus, tumor cells may rely on xCT to fulfill the majority of their potential. However, their clinical benefit is currently limited, as cysteine and GSH needs by importing cystine. only a fraction of patients respond, suggesting that these regimens Inhibition of xCT has been investigated as a therapeutic may benefit from combination with tumor-targeting treatments. As strategy for cancer based on observations that elevated xCT ex- oncogenic progression is accompanied by alterations in metabolic pression on tumor cells correlates with poor prognosis (10–12) pathways, tumors often become heavily reliant on antioxidant and that inhibition of xCT in preclinical studies suppresses tumor machinery and may be susceptible to increases in oxidative stress. growth (10, 12–14). However, these studies relied heavily on the The cystine–glutamate antiporter xCT is frequently overexpressed in use of sulfasalazine, a clinical compound used for the treatment cancer and fuels the production of the antioxidant glutathione; thus, of rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
  • Download Supplementary

    Download Supplementary

    Item Occurences Present In Fever, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Acute Kidney Injury, Neutrophilia, Lymphophenia, Thrombocytopenia, Multiple Organ TNF 16 Failure, SARS-CoV, Viral Life Cycle Cough, Fever, Dyspnea, Pneumonia, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Neutrophilia, CXCL8 15 Leukocytosis, Thrombocytopenia, SARS-CoV, Viral Life Cycle Cough, Fever, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Neutrophilia, IL1B 13 Leukocytosis, Lymphophenia Fever, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Acute Kidney Injury, IL6 13 Neutrophilia, Thrombocytopenia, SARS-CoV Cough, Fever, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Neutrophilia, MMP9 13 Leukocytosis, Multiple Organ Failure Cough, Fever, Dyspnea, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, TGFB1 13 Acute Kidney Injury, Thrombocytopenia Cough, Fever, Pneumonia, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Sepsis, SARS-CoV, Viral Entry, ACE2 12 Viral Life Cycle Fever, Pneumonia, Lung Disease, Diabetes, Hypertension, Cancer, Sepsis, Neutrophilia, Lymphophenia, Thrombocytopenia, CXCR4 12 Viral Entry, Viral Life Cycle Cough, Fever, Dyspnea, Heart Disease, Kidney Disease, Lung Disease, Diabetes, Hypertension, Cancer, Acute Kidney Injury, EGFR 12 Viral Entry, Viral
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Role of Apple Phytochemicals, Phloretin and Phloridzin, in Modulating Processes Related to Intestinal Inflammation

    Role of Apple Phytochemicals, Phloretin and Phloridzin, in Modulating Processes Related to Intestinal Inflammation

    nutrients Article Role of Apple Phytochemicals, Phloretin and Phloridzin, in Modulating Processes Related to Intestinal Inflammation Danuta Zielinska 1, José Moisés Laparra-Llopis 2, Henryk Zielinski 3, Dorota Szawara-Nowak 3 and Juan Antonio Giménez-Bastida 3,4,* 1 Department of Chemistry, University of Warmia and Mazury, 10-727 Olsztyn, Poland; [email protected] 2 Group of Molecular Immunonutrition in Cancer, Madrid Institute for Advanced Studies in Food (IMDEA-Food), 28049 Madrid, Spain; [email protected] 3 Institute of Animal Reproduction and Food Research, Department of Chemistry and Biodynamics of Food, Polish Academy of Science, 10-748 Olsztyn, Poland; [email protected] (H.Z.); [email protected] (D.S.-N.) 4 Group on Quality, Safety and Bioactivity of Plant Foods, Centro de Edafología y Biología Aplicada del Segura (CSIC), 30100 Murcia, Spain * Correspondence: [email protected] Received: 25 April 2019; Accepted: 23 May 2019; Published: 25 May 2019 Abstract: Plant-derived food consumption has gained attention as potential intervention for the improvement of intestinal inflammatory diseases. Apple consumption has been shown to be effective at ameliorating intestinal inflammation symptoms. These beneficial effects have been related to (poly)phenols, including phloretin (Phlor) and its glycoside named phloridzin (Phldz). To deepen the modulatory effects of these molecules we studied: i) their influence on the synthesis of proinflammatory molecules (PGE2, IL-8, IL-6, MCP-1, and ICAM-1) in IL-1β-treated myofibroblasts of the colon CCD-18Co cell line, and ii) the inhibitory potential of the formation of advanced glycation end products (AGEs).
  • Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer

    Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer

    Journal of Nuclear Medicine, published on July 16, 2008 as doi:10.2967/jnumed.107.050021 Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer Corinna von Forstner*1, Jan-Hendrik Egberts*2, Ole Ammerpohl2, Dagmara Niedzielska3, Ralph Buchert3, Pal Mikecz3, Udo Schumacher4, Kersten Peldschus5, Gerhard Adam5, Christian Pilarsky6, Robert Grutzmann6, Holger Kalthoff2, Eberhard Henze1, and Winfried Brenner3 1Department of Nuclear Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 2Department of General Surgery and Thoracic Surgery, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 3Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4Department of Anatomy II Experimental Morphology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5Department of Diagnostic and Interventional Radiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; and 6Department of Visceral, Thoracic, and Vascular Surgery, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany the highest and most consistent uptake in various human pan- Our aim was to use PET/MRI to evaluate and compare the uptake creatic tumor cell lines in SCID mice. The imaging results could of 18F-FDG, 3-deoxy-3-18F-fluorothymidine (18F-FLT), and 18F- be explained by gene expression patterns of membrane trans- fluorethylcholine (18F-FEC) in human pancreatic tumor cell lines porters and enzymes for tracer uptake and retention as mea- after xenotransplantation into SCID mice and to correlate tumor sured by gene array analysis and quantitative polymerase uptake with gene expression of membrane transporters and chain reaction in the respective cell lines.
  • Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors

    Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors

    Reviews Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors Author ABSTRACT Wolfgang Blaschek Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as by regulation of glu- Affiliation cose absorption, gluconeogenesis, biosynthesis and mobiliza- Formerly: Institute of Pharmacy, Department of Pharmaceu- tion of glycogen, glucose consumption in all tissues and glo- tical Biology, Christian-Albrechts-University of Kiel, Kiel, merular filtration, and reabsorption of glucose in the kidneys. Germany Glucose enters or leaves cells mainly with the help of two membrane integrated transporters belonging either to the Key words family of facilitative glucose transporters (GLUTs) or to the Malus domestica, Rosaceae, Phlorizin, flavonoids, family of sodium glucose cotransporters (SGLTs). The intesti- ‑ SGLT inhibitors, gliflozins, diabetes nal glucose absorption by endothelial cells is managed by SGLT1, the transfer from them to the blood by GLUT2. In the received February 9, 2017 kidney SGLT2 and SGLT1 are responsible for reabsorption of revised March 3, 2017 filtered glucose from the primary urine, and GLUT2 and accepted March 6, 2017 GLUT1 enable the transport of glucose from epithelial cells Bibliography back into the blood stream. DOI http://dx.doi.org/10.1055/s-0043-106050 The flavonoid phlorizin was isolated from the bark of apple Published online April 10, 2017 | Planta Med 2017; 83: 985– trees and shown to cause glucosuria. Phlorizin is an inhibitor 993 © Georg Thieme Verlag KG Stuttgart · New York | of SGLT1 and SGLT2. With phlorizin as lead compound, specif- ISSN 0032‑0943 ic inhibitors of SGLT2 were developed in the last decade and some of them have been approved for treatment mainly of Correspondence type 2 diabetes.
  • The Concise Guide to Pharmacology 2019/20

    The Concise Guide to Pharmacology 2019/20

    Edinburgh Research Explorer THE CONCISE GUIDE TO PHARMACOLOGY 2019/20 Citation for published version: Cgtp Collaborators 2019, 'THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters', British Journal of Pharmacology, vol. 176 Suppl 1, pp. S397-S493. https://doi.org/10.1111/bph.14753 Digital Object Identifier (DOI): 10.1111/bph.14753 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L
  • Expression of SLC2A9 Isoforms in the Kidney and Their Localization in Polarized Epithelial Cells

    Expression of SLC2A9 Isoforms in the Kidney and Their Localization in Polarized Epithelial Cells

    Expression of SLC2A9 Isoforms in the Kidney and Their Localization in Polarized Epithelial Cells Toru Kimura1, Michi Takahashi1, Kunimasa Yan2, Hiroyuki Sakurai1* 1 Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan, 2 Department of Pediatrics, Kyorin University School of Medicine, Mitaka, Tokyo, Japan Abstract Background: Many genome-wide association studies pointed out that SLC2A9 gene, which encodes a voltage-driven urate transporter, SLC2A9/GLUT9 (a.k.a. URATv1), as one of the most influential genes for serum urate levels. SLC2A9 is reported to encode two splice variants: SLC2A9-S (512 amino acids) and SLC2A9-L (540 amino acids), only difference being at their N- termini. We investigated isoform-specific localization of SLC2A9 in the human kidney and role of N-terminal amino acids in differential sorting in vitro. Methodology/Principal Findings: Isoform specific antibodies against SLC2A9 were developed and human kidney sections were stained. SLC2A9-S was expressed in the apical side of the collecting duct while SLC2A9-L was expressed in the basolateral side of the proximal tubule. GFP fused SLC2A9s were expressed in MDCK cells and intracellular localization was observed. SLC2A9-S was expressed at both apical and basolateral membranes, whereas SLC2A9-L was expressed only at the basolateral membrane. Although SLC2A9-L has a putative di-leucine motif at 33th and 34th leucine, deletion of the motif or replacement of leucine did not affect its subcellular localization. When up to 16 amino acids were removed from the N- terminal of SLC2A9-S or when up to 25 amino acids were removed from the N-terminal of SLC2A9-L, there was no change in their sorting.
  • The Na+/Glucose Co-Transporter Inhibitor Canagliflozin Activates AMP-Activated Protein Kinase by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

    The Na+/Glucose Co-Transporter Inhibitor Canagliflozin Activates AMP-Activated Protein Kinase by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

    Page 1 of 37 Diabetes Hawley et al Canagliflozin activates AMPK 1 The Na+/glucose co-transporter inhibitor canagliflozin activates AMP-activated protein kinase by inhibiting mitochondrial function and increasing cellular AMP levels Simon A. Hawley1†, Rebecca J. Ford2†, Brennan K. Smith2, Graeme J. Gowans1, Sarah J. Mancini3, Ryan D. Pitt2, Emily A. Day2, Ian P. Salt3, Gregory R. Steinberg2†† and D. Grahame Hardie1†† 1Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, UK 2Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada 3Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, Scotland, UK Running title: Canagliflozin activates AMPK Corresponding authors: Dr. D. G. Hardie, Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, Scotland, UK; Dr. G.R. Steinberg, Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada Tel: +44 (1382) 384253; FAX: +44 (1382) 385507; e-mail: [email protected] Tel: +1 (905) 525-9140 ext.21691; email: [email protected] Word count in main text: 3,996 Number of Figures: 7 †these authors made equal contributions to this study ††joint corresponding authors Diabetes Publish Ahead of Print, published online July 5, 2016 Diabetes Page 2 of 37 Hawley et al Canagliflozin activates AMPK 2 ABSTRACT Canagliflozin, dapagliflozin and empagliflozin, all recently approved for treatment of Type 2 diabetes, were derived from the natural product phlorizin. They reduce hyperglycemia by inhibiting glucose re- uptake by SGLT2 in the kidney, without affecting intestinal glucose uptake by SGLT1.
  • 2.1 Drosophila Melanogaster

    2.1 Drosophila Melanogaster

    Overend, Gayle (2010) Drosophila as a model for the Anopheles Malpighian tubule. PhD thesis, University of Glasgow. http://theses.gla.ac.uk/1604/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] Drosophila as a model for the Anopheles Malpighian tubule A thesis submitted for the degree of Doctor of Philosophy at the University of Glasgow Gayle Overend Integrative and Systems Biology Faculty of Biomedical and Life Sciences University of Glasgow Glasgow G11 6NU UK August 2009 2 The research reported within this thesis is my own work except where otherwise stated, and has not been submitted for any other degree. Gayle Overend 3 Abstract The insect Malpighian tubule is involved in osmoregulation, detoxification and immune function, physiological processes which are essential for insect development and survival. As the Malpighian tubules contain many ion channels and transporters, they could be an effective tissue for targeting with novel pesticides to control populations of Diptera. Many of the insecticide compounds used to control insect pest species are no longer suited to their task, and so new means of control must be found.